Breaking News: KNSA – Market Insights, Analysis & Latest Updates

KNSA

Earnings call: Kiniksa Pharma's Q3 2024 shows strong ARCALYST sales growth

Kiniksa Pharmaceuticals reported a 73% increase in Q3 2024 ARCALYST revenue, raising its sales guidance while continuing to focus on prescriber growth and disease awareness.

investing.com • 30/10/2024 - 21:45 PM

KNSA

Kiniksa Pharmaceuticals COO sells shares worth over $437,000

Tessari Eben, COO of Kiniksa Pharmaceuticals, sold shares worth $437,325 under a trading plan. Kiniksa shows strong revenue growth amid financial optimism and ongoing studies.

investing.com • 25/09/2024 - 20:41 PM

Greed and Fear Index

Note: The data is for reference only.

Greed

Earnings call: Kiniksa Pharma's Q3 2024 shows strong ARCALYST sales growth

Kiniksa Pharmaceuticals COO sells shares worth over $437,000

Currency